耐赋康7项最新真实世界数据将亮相第18届IgA肾病国际研讨会

Core Insights - The article highlights the significant clinical value of Nefecon® in the treatment of IgA nephropathy, demonstrating efficacy in "etiological treatment, early intervention, and long-term treatment" [1][2][3] Group 1: Clinical Data and Evidence - Recent real-world data from top hospitals in China show that Nefecon® effectively reduces proteinuria and stabilizes renal function, with over 9 months of extended treatment providing strong evidence for its long-term efficacy and safety [2][4] - Nefecon® is the only drug recommended in both international and domestic guidelines for the etiological treatment of IgA nephropathy, solidifying its position as a cornerstone therapy [3][11] Group 2: Conference Presentation - Nefecon® will present seven new real-world data studies at the 18th International IgA Nephropathy Symposium (IIgANN 2025) in Prague, Czech Republic, from September 17 to 20, 2025 [1][2] Group 3: Regulatory Approvals and Guidelines - Nefecon® has been included in the 2024 KDIGO guidelines and the Chinese adult IgA nephropathy clinical practice guidelines, marking it as a pivotal treatment option [3] - The drug was successfully added to the National Medical Insurance Drug List in November 2024 and received approval for production expansion from the National Medical Products Administration in August 2025 [3] Group 4: Mechanism of Action - Nefecon® is designed to target intestinal mucosal B cells, reducing the production of pathogenic IgA1, which is implicated in the disease's progression [11]